Profile data is unavailable for this security.
About the company
Helix BioMedix, Inc. is a biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum (XP). The Company is in the preclinical stage of development and intends to file for orphan drug designation prior to entering the clinical development pathway. Its legacy business consists of an proprietary library of patented bioactive peptides. Its lead drug development candidate, HB4208, is a polypeptide DNA deoxyribonucleic (DNA) damage response (DDR) enzyme for topical treatment of the rare genetic disorder (orphan disease) XP. Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is also engaged in the treatment of skin conditions.
- Revenue in USD (TTM)2.07m
- Net income in USD-2.58m
- Incorporated2000
- Employees8.00
- LocationHelix BioMedix Inc19125 Northcreek Parkway Suite 120BOTHELL 98021United StatesUSA
- Phone+1 (425) 402-8400
- Fax+1 (425) 806-2999
- Websitehttps://helixbiomedix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Windtree Therapeutics Inc | 0.00 | -48.83m | 394.39k | 14.00 | -- | -- | -- | -- | -8.38 | -8.38 | 0.00 | -0.3449 | 0.00 | -- | -- | 0.00 | -172.27 | -48.72 | -791.65 | -52.57 | -- | -- | -- | -- | -- | -- | 22.36 | -- | -- | -- | 72.96 | -- | -42.51 | -- |
| Avenue Therapeutics Inc | 1.40m | -3.74m | 477.51k | 2.00 | -- | 0.1343 | -- | 0.3401 | -1.55 | -1.55 | 0.50 | 1.12 | 0.4422 | -- | -- | 702,000.00 | -119.06 | -159.81 | -122.59 | -215.40 | -- | -- | -269.23 | -- | -- | -- | 0.00 | -- | -- | -- | -12.29 | -- | -- | -- |
| Regenerative Medical Technology Grop Inc | 5.04m | -7.06m | 512.42k | 1.00 | -- | -- | -- | 0.1017 | -0.5629 | -0.5629 | 0.4019 | -2.40 | 1.30 | 24.95 | 69.50 | -- | -182.18 | -177.25 | -- | -- | 59.76 | 64.83 | -140.06 | -465.06 | 0.0784 | -0.0279 | -- | -- | 70.44 | 167.30 | 43.31 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -11.18m | 536.04k | 10.00 | -- | -- | -- | -- | -1.71 | -1.71 | 0.00 | -0.866 | 0.00 | -- | -- | 0.00 | -611.66 | -81.00 | -- | -90.58 | -- | -- | -- | -- | -- | -65.76 | -- | -- | -- | -- | 38.46 | -- | -- | -- |
| Longevity Health Holdings Inc | 1.46m | -5.74m | 545.07k | 15.00 | -- | -- | -- | 0.374 | -5.22 | -5.22 | 1.26 | -2.23 | 0.5077 | 1.11 | 47.31 | 97,153.34 | -199.84 | -- | -- | -- | 57.86 | -- | -393.63 | -- | 0.2676 | -- | -- | -- | -- | -- | 36.91 | -- | -- | -- |
| Novelstem International Corp | 3.00k | 2.31m | 562.58k | 15.00 | 0.2495 | -- | -- | 187.53 | 0.0481 | 0.0481 | 0.00006 | -0.0438 | 0.0281 | -- | 0.80 | -- | 630.69 | -- | -- | -- | -- | -- | 22,424.33 | -- | -- | -- | -- | -- | 0.00 | -- | 22.79 | -- | -- | -- |
| Helix BioMedix Inc | 2.07m | -2.58m | 609.46k | 8.00 | -- | 0.3887 | -- | 0.295 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| PMGC Holdings Inc | 285.95k | -4.48m | 696.95k | 2.00 | -- | 0.03 | -- | 2.44 | -57.57 | -129.01 | 3.93 | 45.64 | 0.0219 | 0.373 | 1.98 | 142,975.00 | -34.29 | -- | -48.32 | -- | 27.29 | -- | -1,567.42 | -- | 1.77 | -32.16 | 0.2734 | -- | -- | -- | -142.45 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -9.17m | 697.22k | 22.00 | -- | 0.4279 | -- | -- | -13.39 | -13.39 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -245.96 | -65.13 | -417.51 | -73.82 | -- | -- | -- | -- | -- | -5.25 | 0.0606 | -- | -- | -- | 73.04 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 763.78k | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Protagenic Therapeutics Inc | -100.00bn | -100.00bn | 773.95k | 1.00 | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2945 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -49.19m | 835.39k | 8.00 | -- | -- | -- | -- | -175.56 | -175.56 | 0.00 | -3.04 | 0.00 | -- | -- | 0.00 | -282.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.12 | -- | -- | -- |
